scout

Authors

Gerard A. Silvestri, MD, MS
Latest Article

New Testing for Lung Cancer Screening

In this review, the authors discuss past attempts at lung cancer screening, the results of the National Lung Cancer Screening Trial, and innovative tests for lung cancer screening currently being evaluated.

Gerard Bastian, PhD
Latest Article

Impact of UFT on Tumoral TS and DPD Levels in Colorectal Cancer

This was an open lable, pilot translational clinical pharmacology study of a brief (7 day) course of UFT, 300 mg/m²/day, in combination with leucovorin, 90 mg/day, in six patients with newly diagnosed advanced colorectal cancer.

Gerard M. Doherty, MD
Latest Article

Prophylactic Central Lymph Node Dissection: Continued Controversy

Low-risk papillary thyroid carcinoma (PTC), by definition, requires careful balancing of the risks of treatment and the risks of the disease.

Gerard Milano, PhD
Latest Article

Impact of UFT on Tumoral TS and DPD Levels in Colorectal Cancer

This was an open lable, pilot translational clinical pharmacology study of a brief (7 day) course of UFT, 300 mg/m²/day, in combination with leucovorin, 90 mg/day, in six patients with newly diagnosed advanced colorectal cancer.

Gerasimos Aravantinos, MD
Latest Article

Paclitaxel and Carboplatin as First-Line Chemotherapy for Advanced Breast Cancer

In a phase II study, 66 patients with advanced breast cancer (median age 56 years; range, 28 to 75 years) were treated with paclitaxel (Taxol), 175 mg/m² infused over 3 hours, and carboplatin (Paraplatin), dosed to attain an

Gerold Bepler, MD, PhD
Latest Article

Neoadjuvant Chemotherapy for Resectable Non–Small-Cell Lung Cancer

Lung cancer is the most common cancer diagnosed in men and women in the United States, and is the leading cause of cancer death.Over 160,000 individuals died as a result of lung cancer in 2008.[1] This number amounted to more than the number of deaths from colon, breast, and prostate cancers combined. The majority of lung cancer cases are non–small-cell lung cancer (NSCLC), and the poor outcomes are attributed to the high rate of metastases associated with this disease.

Gerry Oster, PhD
Latest Article

Hospitalization for 5-FU Toxicity in Metastatic Colorectal Cancer: Incidence and Cost

Although treatment with 5-fluorouracil (5-FU) plus calcium folinate has been reported to prolong survival in patients with metastatic colorectal cancer, it can also cause significant toxicity, potentially resulting in

Gertraud Maskarinec, MD, PhD
Latest Article

It’s Time for Clinicians to Reconsider Their Proscription Against the Use of Soyfoods by Breast Cancer Patients

Recently published research questions the need for the advised restriction against the use of soyfoods by women with a history of breast cancer.

Ghassan Al-jazayrly, MD
Latest Article

A Clinician’s Perspective on ASCO 2001: Going After the Epidermal Growth Factor Receptor

Among the most exciting new anticancer products presented at the 2001 ASCO meeting were new drugs that block the epidermal growth factor receptor (EGFR). About 30% to 90% of carcinomas express high levels of EGFR. These include, among others, head and neck cancer, lung cancer, pancreatic cancer, colon cancer, breast cancer, ovarian cancer, and bladder cancer.

Giada Bianchi, MD
Latest Article

The Heavy Chain Diseases: Clinical and Pathologic Features

This review discusses the clinical presentation; epidemiology; laboratory, radiologic, and pathologic features; and treatment options for each of the heavy chain diseases, emphasising the importance of an accurate pathologic diagnosis and correct interpretation of immunologic studies in their identification.

Giampaolo Merlini, MD
Latest Article

Uniform Risk-Stratification and Response Criteria Are Paving the Way to Evidence-Based Treatment of AL Amyloidosis

In less than a decade, the resources available to treat light chain (AL) amyloidosis have increased impressively.

Gian Luigi Cetto, MD
Latest Article

Gemcitabine/Epirubicin/Paclitaxel Trials in Advanced Breast Cancer

Numerous trials have shown that the pharmacokinetic interferences of epirubicin (Ellence)/paclitaxel (Taxol) combinations produce less pharmacodynamic effect than doxorubicin/paclitaxel regimens. Paclitaxel is more easily

Gijsberta J. Van Londen, MD, MS
Latest Article

Breast Cancer: Never Too Young for a Functional Assessment?

Geriatricians would argue that biological age alone should not be used to estimate a patient's anticipated tolerance for cancer therapy.

Gilbert (gib) Smith, JD
Latest Article

Fraudulent Interpretation of Lab Results

In this edition, we offer an example of how clinicians and patients can be fooled and/or injured by fraudulent healthcare practitioners and their services. The clinical care team must be sure that the references it provides to patients are safe and reliable. Keep a list of reliable references and a list of those practitioners and services/treatments that should be avoided. Maintain an open door policy with your patients designed to encourage questions and exchange such information.

Gilbert A. Lawrence, MD, DMRT, FRCR
Latest Article

Maximizing Radiation Benefit in Breast Cancer

We read with interest the article and reviews of "Current Status of Radiation in the Treatment of Breast Cancer," which appeared in the April 2001 issue of ONCOLOGY.[1] These papers suggest that one of the most controversial areas in this

Gilbert G. Fareau, MD
Gilberto Schwartsmann, MD, PhD
Latest Article

A Phase II Study of Doxorubicin/Paclitaxel Plus G-CSF for Metastatic Breast Cancer

This phase II trial was conducted to evaluate the percentage of objective responses and the toxicity profile of combination doxorubicin (Adriamycin) and paclitaxel (Taxol) with granulocyte colony-stimulating factor as first-line

Gina Brown, MD, FRCR
Latest Article

Guiding Post-Treatment Decisions in Rectal Cancer: mrTRG Is a Practical Place to Start

The authors propose that current policies regarding the use of chemoradiotherapy or short-course preoperative radiotherapy have resulted in an approach to rectal cancer management that often represents overtreatment, with significant loss of quality of life for patients.

Gina G. Chung, MD
Latest Article

Tailoring Endocrine Therapy in Breast Cancer Patients

The majority of invasive breast cancer patients present with hormone receptor-positive disease, and modulation of estrogen receptor (ER) activation is an essential component of systemic adjuvant therapy for these women. While tamoxifen has traditionally been the primary adjuvant endocrine therapy for all ER-positive women, recent trials evaluating the use of aromatase inhibitors (AIs) have challenged this standard in postmenopausal women, and ongoing trials are examining the optimal use of endocrine therapy in younger women. Issues regarding the optimal approach to endocrine therapy in both pre- and postmenopausal women are examined in this review.

Gini F. Fleming, MD
Latest Article

POINT: LHRH Agonists vs Ovarian Ablation for Suppression of Ovarian Function in Premenopausal Breast Cancer Patients

Reversible ovarian function suppression using LHRH agonists is the preferred first treatment for most premenopausal breast cancer patients.

Ginny Mason, RN
Latest Article

Management of a Patient With Inflammatory Breast Cancer

Two years after her first mammogram the patient, EC, noticed swelling and skin changes in one breast. A bone scan, chest and abdomen CT, and PET scan were negative for metastatic spread, staging the cancer at IIIB.

Giorgio Gandaglia, MD
Latest Article

Node-Positive Prostate Cancer: A Call for Level 1 Evidence

Despite the lack of level 1 evidence, retrospective studies support the need for appropriate local treatment, even in the context of node-positive disease.

Giorgio V. Scagliotti, MD, PhD
Latest Article

Histologic Subtype in NSCLC: Does It Matter?

Since the publication of a meta-analysis in 1995 that demonstrated a modest survival benefit compared to best supportive care, platinum-based chemotherapy became the cornerstone of therapy in the first-line setting in advanced-stage non–small-cell lung cancer (NSCLC) for patients with good performance status.[1] A recent meta-analysis of 16 randomized trials including 2,714 patients demonstrated an advantage of chemotherapy over best supportive care with an absolute improvement in survival of 9% at 12 months.[2]

Giorgio Vittorio Scagliotti, MD
Latest Article

Gemcitabine/Cisplatin as Induction Therapy for Stage IIIA N2 Non–Small-Cell Lung Cancer

Because the majority of patients with stage IIIA N2 non–small-cell lung cancer (NSCLC) ultimately die of distant metastases, recent efforts to improve their intermediate- and long-term survival have focused on neoadjuvant

Giovanna Finocchiaro, MD
Latest Article

Perspectives on Salvage Therapy for Non–Small-Cell Lung Cancer

Platinum-based chemotherapy offers a modest survival advantage overbest supportive care in chemotherapy-naive patients with a good performancestatus and advanced/metastatic non–small-cell lung cancer(NSCLC). Despite the survival benefit associated with first-line chemotherapy,the majority of patients will experience relapse or disease progression.In clinical practice, an increasing number of patients maintaina good performance status after first-line treatment and are eligible forfurther treatments. Docetaxel (Taxotere) at 75 mg/m2 given once every3 weeks has been the standard of care for second-line chemotherapy sincethe year 2000. Pemetrexed (Alimta) is a novel multitargeted antifolateagent with single-agent activity in first- and second-line treatment ofNSCLC. A large phase III study comparing docetaxel to pemetrexed insecond-line therapy demonstrated that pemetrexed is equally active andless toxic than docetaxel. Based on these results, pemetrexed is a reasonablesecond-line chemotherapy option for patients with recurrent, advancedNSCLC. Progress made in the field of molecular biology has led to theidentification of drugs active against specific cellular targets. Gefitinib(Iressa) and erlotinib (Tarceva) are both orally active tyrosine kinase inhibitorsof the epidermal growth factor receptor. Phase II and III trialshave demonstrated that these agents are active particularly in a subgroupof patients with specific biologic characteristics. Both drugs have beenapproved for the treatment of pretreated NSCLC. Other drugs, such ascetuximab (Erbitux) and bevacizumab (Avastin) have shown promisingactivity in NSCLC and are currently being tested in clinical trials.

Giovanni Begossi, MD
Latest Article

Commentary (Begossi/Wanebo): Surgery in the Older Patient

With this insightful manuscript, Drs. Termuhlen and Kemeny shed some light on the surgical management of older cancer patients. The authors highlight pitfalls in patient selection and offer proposals to improve the surgical oncologist’s approach to patient care. They review the role of curative surgical management of the most common forms of cancer in the elderly, while emphasizing the role of surgical palliation to improve the quality of life of older cancer patients.

Giovanni D. Aletti, MD
Latest Article

Ovarian Cancer Care: It’s Time for “Personalized” Approaches

As outlined in the excellent, comprehensive review by Drs. Liu and Matulonis, ovarian cancer is the most lethal gynecologic malignancy in the United States, with approximately 16,000 deaths and 22,000 new cases yearly.[1] The vast majority of patients present with intra-abdominal spread of disease at the time of diagnosis, resulting in low overall cure rates. As outlined, patients are primarily managed with primary surgical resection and subsequent platinum-based chemotherapy.

Giovanni Luca Frassineti, MD
Latest Article

Doxorubicin and Paclitaxel (Sequential Combination) in the Treatment

Based on preclinical data, we designed a phase I/II clinical trial to determine the efficacy and toxicity of doxorubicin followed by paclitaxel in the treatment of advanced breast cancer (either untreated or relapsed after

Giovanni Palladini, MD, PhD
Latest Article

Uniform Risk-Stratification and Response Criteria Are Paving the Way to Evidence-Based Treatment of AL Amyloidosis

In less than a decade, the resources available to treat light chain (AL) amyloidosis have increased impressively.

Giovanni Scambia, MD
Latest Article

COUNTERPOINT: Primary Debulking Surgery vs Neoadjuvant Chemotherapy for Newly Diagnosed Advanced Ovarian Cancer

In a Significant Percentage of Patients, Neoadjuvant Therapy Yields Equivalent Survival, With Better Quality of Life and Lower Costs